Miller-Sims Vanessa C, Petri William A
Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Curr Opin Immunol. 2002 Oct;14(5):549-52. doi: 10.1016/s0952-7915(02)00372-2.
The development of a vaccine against Entamoeba histolytica, the causative agent of amebic colitis and liver abscess, would reduce childhood mortality in countries such as Bangledesh where community-based studies have demonstrated a high prevalence of E. histolytica. Immunological studies from this population have shown that protection from amebiasis is associated with mucosal anti-E. histolytica Gal/GalNAc lectin antibodies, suggesting that a vaccine is an achievable goal. However, garnering resources for vaccine development is a challenge when the vaccine is targeted to poor people living in developing countries.
开发针对溶组织内阿米巴这一引起阿米巴结肠炎和肝脓肿的病原体的疫苗，将降低孟加拉国等国儿童的死亡率，在这些国家基于社区的研究已证明溶组织内阿米巴感染率很高。该人群的免疫学研究表明，预防阿米巴病与黏膜抗溶组织内阿米巴半乳糖/ N - 乙酰半乳糖胺凝集素抗体有关，这表明疫苗是一个可以实现的目标。然而，当疫苗针对生活在发展中国家的贫困人口时，为疫苗开发筹集资源是一项挑战。
